DLBCL Patient Profiling and Treatment Evaluation

Lymph node samples were collected from 100 newly diagnosed DLBCL patients and 20 lymphoid reactive hyperplasia (RHL) patients. The diagnostic criteria were established according to the World Health Organization (WHO) classification 30 (link). Among them, 65 enrolled DLBCL patients received treatment, of which 49 documented the treatment regimens and response (Table S1). Besides, the response was evaluated after every three courses of treatment, mainly based on positron emission tomography/computed tomography (PET/CT) results (Table S1). Peripheral blood mononuclear cells (PBMCs) of healthy donors were isolated by the Ficoll-Hypaque density gradient centrifugation method (TBD Science, Tianjin, China) and naïve CD19⁺ B-cells were separated by CD19⁺ magnetic microbeads kit (Miltenyi Biotec, Bergisch Gladbach, Germany). The purity of enriched CD19⁺ B-cells was detected by flow cytometry (FCM) analysis, as previously reported (Figure S1A) 31 (link).